Clinical trial
A Phase III, Randomized, Double-blind, Multiple Doses, Placebo-controlled, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Atropine for the Treatment of Myopia Progression in Children and Adolescents (MODERATO Study)
NCT07028827 is registered in ClinicalTrials.gov with Ocus Innovation Ireland Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double-blind, Multiple Doses, Placebo-controlled, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Atropine for the Treatment of Myopia Progression in Children and Adolescents (MODERATO Study)
- Lead sponsor
- Ocus Innovation Ireland Limited
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 1, 2025
- Completion date
- December 31, 2027
- Enrollment
- 234 (estimated)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.